Human medicines European public assessment report (EPAR): Qezzaqar, catequentinib, Status: Opinion
Human medicines European public assessment report (EPAR): Susvimo, ranibizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Ubeslo, obicetrapib, Status: Opinion
Human medicines European public assessment report (EPAR): Zokovea, ensitrelvir, Status: Opinion
Summary of opinion: Rinvoq, 23/07/2026 Positive
Summary of opinion: Repatha, 23/07/2026 Positive
Summary of opinion: Trixeo Aerosphere, 23/07/2026 Positive
Summary of opinion: Piqray, 23/07/2026 Positive
Summary of opinion: Riltrava Aerosphere, 23/07/2026 Positive
First oral medicine targeting interleukin-23 receptor recommended for plaque psoriasis